Morgan & Morgan Announces Investigation of MAP Pharmaceuticals (NASDAQ: MAPP)

NEW YORK, Jan. 30, 2013 /PRNewswire/ -- Morgan & Morgan is investigating the Board of Directors of MAP Pharmaceuticals Inc. ("MAP" or the "Company") (Nasdaq: MAPP) for possible breaches of fiduciary duty and other violations of law related to the sale of the Company to Allergan Inc.

If you are a current shareholder of MAP and are interested in learning more about our MAP Pharmaceuticals merger investigation, please contact George Pressly, Esq. at 1 (800) 631-6234 or email George at [email protected].

Under the terms of the transaction, MAP shareholders will receive $25 for each share of MAP stock they own. The transaction has a total approximate value of $958 million. The investigation concerns whether the MAP Board of Directors has breached its fiduciary duties to act in the best interests of MAP shareholders and to take all necessary steps to ensure that MAP shareholders receive the maximum value readily available for their shares of MAP common stock.

About Morgan & Morgan
Morgan & Morgan is one of the nation's largest 200 law firms. In addition to securities fraud, the firm also practices in the areas of antitrust, personal injury, consumer protection, overtime, and product liability.  All of the Firm's legal endeavors are rooted in its core mission: provide investor and consumer protection and always fight "for the people." 

Attorney advertising. Prior results do not guarantee a similar outcome.

Contact:
Morgan & Morgan
Peter Safirstein, Esq.
28 West 44^th Street
Suite 2001
New York, NY  10036
1-800-631-6234
[email protected]

SOURCE Morgan & Morgan

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED